C Delaugerre

Summary

Country: France

Publications

  1. ncbi Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication
    C Delaugerre
    Virology Department, Saint Louis Hospital APHP, INSERM U941 Paris 7 Diderot University, Paris, France
    HIV Med 13:517-25. 2012
  2. ncbi Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients
    Constance Delaugerre
    Laboratoire de Virologie, Hôpital Saint Louis APHP, Paris, France
    PLoS ONE 7:e36673. 2012
  3. ncbi Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen
    Constance Delaugerre
    Virology Department, Saint Louis Hospital APHP, Paris, France
    AIDS 22:1809-13. 2008
  4. ncbi Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy
    Constance Delaugerre
    University Paris Descartes, EA 3620, Virology Department, Necker Hospital AP HP, Paris, France
    Antimicrob Agents Chemother 53:2934-9. 2009
  5. ncbi Clinical and resistance consequences of misquantification of plasma and cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype G-infected patient
    Constance Delaugerre
    Department of Virology, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75010 Paris, France
    J Clin Microbiol 47:3763-4. 2009
  6. ncbi Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome
    Constance Delaugerre
    EA 3620 MRT, Descartes University, Paris, France
    Retrovirology 6:85. 2009
  7. ncbi National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation
    C Delaugerre
    CHU Ambroise Pare, Boulogne, France
    J Med Virol 80:762-5. 2008
  8. ncbi [Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor]
    C Delaugerre
    Universite Paris Diderot, Laboratoire de Virologie, Hopital Saint Louis, AP HP, 1 avenue Claude Vellefaux, 75010 Paris, France
    Med Mal Infect 40:S1-10. 2010
  9. ncbi Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen
    Constance Delaugerre
    Virology Department, INSERM U941 Paris 7 Diderot University, Saint Louis Hospital APHP, Paris, France
    AIDS 24:2391-5. 2010
  10. ncbi Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study)
    C Delaugerre
    Department of Virology, Saint Louis Hospital APHP, 75010 Paris, France
    J Clin Virol 47:248-52. 2010

Collaborators

Detail Information

Publications52

  1. ncbi Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication
    C Delaugerre
    Virology Department, Saint Louis Hospital APHP, INSERM U941 Paris 7 Diderot University, Paris, France
    HIV Med 13:517-25. 2012
    ..We examined whether genotyping based on cellular HIV-1 DNA during controlled viraemia identifies resistance mutations detected in plasma HIV-1 RNA during treatment with previous antiretroviral regimens...
  2. ncbi Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients
    Constance Delaugerre
    Laboratoire de Virologie, Hôpital Saint Louis APHP, Paris, France
    PLoS ONE 7:e36673. 2012
    ..Our objective was to determine the emergence and evolution of DRAM during LLV in HIV-1-infected patients while receiving antiretroviral therapy (ART)...
  3. ncbi Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimen
    Constance Delaugerre
    Virology Department, Saint Louis Hospital APHP, Paris, France
    AIDS 22:1809-13. 2008
    ..Limited data are available on resistance pattern emerging in patients failing DRV/r and on subsequent remaining protease inhibitor options...
  4. ncbi Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy
    Constance Delaugerre
    University Paris Descartes, EA 3620, Virology Department, Necker Hospital AP HP, Paris, France
    Antimicrob Agents Chemother 53:2934-9. 2009
    ..The mutation L76V may be considered in further studies of lopinavir resistance...
  5. ncbi Clinical and resistance consequences of misquantification of plasma and cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype G-infected patient
    Constance Delaugerre
    Department of Virology, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75010 Paris, France
    J Clin Microbiol 47:3763-4. 2009
    ..We report a case of underquantification of HIV type 1 (HIV-1) RNA in plasma and cerebrospinal fluid from an HIV-1 subtype G-infected woman, leading to delayed diagnosis of HIV encephalitis and to the emergence of drug resistance...
  6. ncbi Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome
    Constance Delaugerre
    EA 3620 MRT, Descartes University, Paris, France
    Retrovirology 6:85. 2009
    ..Primary-HIV-1-infection in newborns that occurs under antiretroviral prophylaxis that is a high risk of drug-resistance acquisition. We examine the frequency and the mechanisms of resistance acquisition at the time of infection in newborns...
  7. ncbi National survey of the prevalence and conditions of selection of HIV-1 reverse transcriptase K70E mutation
    C Delaugerre
    CHU Ambroise Pare, Boulogne, France
    J Med Virol 80:762-5. 2008
    ..In conclusion, the K70E mutation could be an alternative pathway of TDF resistance, but as the K65R mutation, other NRTI as ABC, ddI, and 3TC could be also associated with the K70E selection...
  8. ncbi [Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor]
    C Delaugerre
    Universite Paris Diderot, Laboratoire de Virologie, Hopital Saint Louis, AP HP, 1 avenue Claude Vellefaux, 75010 Paris, France
    Med Mal Infect 40:S1-10. 2010
    ....
  9. ncbi Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimen
    Constance Delaugerre
    Virology Department, INSERM U941 Paris 7 Diderot University, Saint Louis Hospital APHP, Paris, France
    AIDS 24:2391-5. 2010
    ..In vitro, integrase inhibitors reduce proviral DNA levels and rapidly increase 2-long-terminal repeat (LTR) circle levels. We examined the effect of raltegravir on the time course of HIV-1 DNA forms in patients with controlled viremia...
  10. ncbi Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study)
    C Delaugerre
    Department of Virology, Saint Louis Hospital APHP, 75010 Paris, France
    J Clin Virol 47:248-52. 2010
    ..Darunavir (DRV) is the latest protease inhibitor (PI) to be approved for antiretroviral-naive and -experienced HIV-infected patients...
  11. ncbi Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure
    C Delaugerre
    Department of Virology, , Paris, France
    AIDS 15:2189-91. 2001
    ..The outgrowth of residual wild-type virus seems not to be a true genetic reversion because drug mutations are detected rapidly at salvage therapy re-initiation...
  12. ncbi Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure
    Anne Genevieve Marcelin
    Department of Virology, Pitié Salpêtrière Hospital and University Paris VI Pierre et Marie Curie, Paris, France
    J Med Virol 72:162-5. 2004
    ....
  13. ncbi Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    J Med Virol 74:16-20. 2004
    ..There was no relation between the resistance pathways selected with either APV or ritonavir plasma minimal concentration, but higher APV plasma minimal concentration were associated with a lower rate of resistance mutations selection...
  14. ncbi Key amprenavir resistance mutations counteract dramatic efficacy of darunavir in highly experienced patients
    Constance Delaugerre
    Department of Virology, Ambroise Pare Hospital, APHP, Boulogne, France
    AIDS 21:1210-3. 2007
    ..These key amprenavir mutations were also selected at the time of failure, suggesting their impact on darunavir efficacy...
  15. ncbi Longitudinal analysis of integrase N155H variants in heavily treated patients failing raltegravir-based regimens
    H L Nguyen
    Virology Department, Saint Louis Hospital, Assistance Publique Hopitaux de Paris, INSERM U941, Paris Diderot University, Sorbonne Paris Cité, Paris, France
    HIV Med 14:85-91. 2013
    ....
  16. ncbi Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial
    Nathalie de Castro
    Department of Infectious Diseases, Assistance Publique Hopitaux de Paris, Saint Louis Hospital and University of Paris VII Denis Diderot, Paris, France
    Clin Infect Dis 49:1259-67. 2009
    ..We conducted a prospective, randomized, open-label trial to compare the antiviral efficacy and safety of a switch to raltegravir with the efficacy and safety of continuing enfuvirtide...
  17. ncbi Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen
    C Delaugerre
    Department of Virology, , , 75013 Paris, France
    J Med Virol 65:445-8. 2001
    ..The use of a thymidine analog concomitantly with nevirapine leads to the preferential selection of cross-resistance NNRTI mutations...
  18. ncbi Virological and pharmacological factors associated with virological response to salvage therapy after an 8-week of treatment interruption in a context of very advanced HIV disease (GigHAART ANRS 097)
    Constance Delaugerre
    Department of Virology, Pitié Salpetrière Hospital Paris, Paris, France
    J Med Virol 77:345-50. 2005
    ..These results suggest that pharmacological enhancement might overcome viral resistance and that there is some benefit in adding the activity of several boosted-PIs to improve the response to a salvage regimen...
  19. ncbi Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs
    Marc Wirden
    Department of Virology, , Bichat Hospital, Paris, France
    J Clin Microbiol 41:2713-5. 2003
    ..These data suggest that these compounds have lost all of their in vivo antiviral activity in such cases...
  20. ncbi Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy
    Marc Wirden
    Department of Virology, INSERM EMI 0214, Pitie Salpetriere Hospital, Paris, France
    Antimicrob Agents Chemother 48:644-7. 2004
    ....
  21. ncbi Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey
    Constance Delaugerre
    Department of Virology EA3620, Necker Hospital, Paris, France
    AIDS 21:1365-7. 2007
    ..In both cases, infection was caused by CCR5 viruses and no rapid clinical progression to AIDS after primary infection was observed...
  22. ncbi Low-rate emergence of thymidine analogue mutations and multi-drug resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus lamivudine combination therapy
    M Mouroux
    Department of Virology, , Paris, France
    Antivir Ther 6:179-83. 2001
    ..One hypothesis explaining these results could be the development of the M184V mutation...
  23. ncbi Factors associated with virological response to etravirine in nonnucleoside reverse transcriptase inhibitor-experienced HIV-1-infected patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
    Antimicrob Agents Chemother 54:72-7. 2010
    ..In conclusion, ETR was associated with high response rates in NNRTI-experienced patients in combination with other active drugs regardless of the therapeutic class used...
  24. ncbi [HIV-1 drug resistance in French infected-children: from newborn to adolescent]
    C Delaugerre
    Laboratoire de Virologie, Hopital Necker Enfants Malades, 149, rue de Sevres, 75015 Paris, France
    Arch Pediatr 14:298-302. 2007
    ..Consequences of long term therapeutic strategies in children are major...
  25. ncbi Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial
    Vincent Calvez
    Department of Virology and Infectious Diseases and Pitie Salpetrière Hospital, Paris, France
    Antivir Ther 7:211-8. 2002
    ....
  26. ncbi Prognostic factors for virological response in antiretroviral therapy-naive patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone
    Philippe Flandre
    INSERM U 943, Paris, France
    Antivir Ther 14:93-7. 2009
    ..The objective of this study was to determine prognostic factors of VR in patients receiving LPV/r monotherapy...
  27. ncbi Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial)
    Constance Delaugerre
    Department of Virology-EA2387, , Paris, France
    Antivir Ther 8:233-7. 2003
    ..CONCLUSION: Administration of IL-2 combined with HAART in HIV-1 infected-patients with advanced disease led to an increase of HIV-1 pro-viral DNA per million PBMC without virological failure or emergence of resistance...
  28. ncbi Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF
    Constance Delaugerre
    Department of Virology, Necker Enfants Malades Hospital, 149 rue de Sevres, 75015 Paris, France
    J Clin Virol 32:241-4. 2005
    ..The high selective pressure on the same resistance pathway was probably associated with the loss of antiviral potency, even in well-controlled patient...
  29. ncbi Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine
    Constance Delaugerre
    Department of Virology, , Paris, France
    Antimicrob Agents Chemother 46:1586-8. 2002
    ....
  30. ncbi Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir
    Constance Delaugerre
    Service de Virologie EA 3620, Hopital Necker Enfants Malades, Paris, France
    J Acquir Immune Defic Syndr 37:1269-75. 2004
    ..In pretreated children, LPV plasma levels should be optimized in an attempt to achieve sufficient drug concentrations to overcome the resistance level...
  31. ncbi Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients
    Anne Genevieve Marcelin
    Department of Virology, Pitie Salpetriere Hospital, Paris, France
    Antimicrob Agents Chemother 48:4687-92. 2004
    ....
  32. ncbi Impact of 48 week lopinavir/ritonavir monotherapy on blood cell-associated HIV-1-DNA in the MONARK trial
    Véronique Avettand-Fenoel
    AP HP, Laboratoire de Virologie, CHU Necker Enfants Malades, Paris, France
    J Antimicrob Chemother 65:1005-7. 2010
    ..To study the impact of protease inhibitor monotherapy on the HIV-1 blood reservoir in 72 antiretroviral-naive patients...
  33. ncbi Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients
    Anne Genevieve Marcelin
    Department of Virology, INSERM EMI 0214, Bichat Claude Bernard Hospital, Paris, France
    Antimicrob Agents Chemother 47:594-600. 2003
    ....
  34. ncbi Change to a once-daily combination including boosted atazanavir in HIV-1-infected children
    Eugenia Macassa
    , Paris, France
    Pediatr Infect Dis J 25:809-14. 2006
    ..CONCLUSION: In these children with extensive previous treatment, the change to a once-daily treatment, including ritonavir-boosted atazanavir, was associated with a significant risk of virologic failure...
  35. ncbi Increasing prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-infected patients from 2001 to 2006/2007 in France
    Diane Descamps
    Laboratoire de Virologie, AP HP Groupe hospitalier Bichat Claude Bernard and EA 4409 Université Paris Diderot Paris 7, Paris, France
    J Antimicrob Chemother 65:2620-7. 2010
    ..To estimate the prevalence of transmitted drug resistance mutations and non-B subtype circulation in antiretroviral-naive chronically HIV-1-infected patients in France...
  36. ncbi Persistence of multidrug-resistant HIV-1 without antiretroviral treatment 2 years after sexual transmission
    Constance Delaugerre
    Department of Virology-EA2387 and Infectious Diseases, , Paris, France
    Antivir Ther 9:415-21. 2004
    ..This work was presented in part in the XII International HIV Drug Resistance Workshop, Los Cabos, Mexico, June 2003; and in the 2nd IAS Conference on HIV Pathogenesis & Treatment, Paris, France, July 2003...
  37. ncbi HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors
    Jade Ghosn
    Universite Paris Descartes, EA MRT 3620, Laboratoire de Virologie, AP HP, CHU Necker Enfants Malades, Paris, France
    AIDS Rev 11:165-73. 2009
    ..The first data on rilpivirine resistance are encouraging, but still too preliminary...
  38. ncbi Age-related differences in the pharmacokinetics of stavudine in 272 children from birth to 16 years: a population analysis
    V Jullien
    Université Paris Descartes Faculté de Médecine, France
    Br J Clin Pharmacol 64:105-9. 2007
    ..To develop a population pharmacokinetic model for stavudine in children and to investigate the consistency of the currently recommended dose based on adult target concentrations...
  39. ncbi Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France
    Marie Laure Chaix
    Université Paris Descartes EA 3620, AP HP, Laboratoire de Virologie, CHU Necker Enfants Malades, Paris, France
    AIDS 23:717-24. 2009
    ....
  40. ncbi Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study
    Dominique Costagliola
    INSERM, Unité Mixte de Recherche UMR S 720, Universite Pierre et Marie Curie Paris 6, Paris, France
    J Acquir Immune Defic Syndr 46:12-8. 2007
    ..Surveillance of HIV-1 drug resistance in antiretroviral-treated patients is important from the public health perspective of the spread of resistance and to evaluate the proportion of patients for whom new drugs are needed...
  41. ncbi Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance
    Diane Descamps
    Laboratoire de Virologie, CHU Bichat Claude Bernard, Paris, France
    J Med Virol 78:153-60. 2006
    ..077). No errors were made by 19% of laboratories in 2002, compared to 42% in 2003. These results show the value of repeated external quality assessments...
  42. ncbi Prevalence and risk factors associated with antiretroviral resistance in HIV-1-infected children
    Constance Delaugerre
    Department of Virology, Necker Hospital, Paris, France
    J Med Virol 79:1261-9. 2007
    ..In conclusion, antiretroviral resistance is common among treated HIV-1-infected children and prevalence was similar with those observed in adult population in the same year period. However, adolescent boys seem to be at greater risk...
  43. ncbi Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients
    Jean Francois Delfraissy
    AP HP, Department of Internal Medicine and Infectious Diseases, Bicetre University Hospital, Le Kremlin Bicetre, France
    AIDS 22:385-93. 2008
    ..Guidelines for the use of antiretroviral agents for HIV-1 infection recommend combining at least three agents. The toxicity, cost, and complexity of such regimens warrant the search for other options...
  44. ncbi HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide
    Diane Descamps
    AP HP, Groupe Hospitalier Bichat Claude Bernard, Laboratoire de Virologie, Paris F 75018, France
    J Antimicrob Chemother 62:451-5. 2008
    ..We studied gp41 mutations associated with failing enfuvirtide salvage therapy...
  45. ncbi Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 years
    Vincent Jullien
    Service de Pharmacologie Clinique, Groupe Hospitalier Cochin Saint Vincent De Paul, 74 82 Avenue Denfert Rochereau, 75674 Paris Cedex 14, France
    Antimicrob Agents Chemother 50:3548-55. 2006
    ..The consequences of these pharmacokinetic discrepancies and the necessity to modify the currently recommended dosage regimen should be further investigated...
  46. ncbi [Therapeutic strategies for HIV infection: boost antiproteases in pediatrics]
    C Delaugerre
    Laboratoire de Virologie, , France
    Med Mal Infect 34:S205-8. 2004
  47. ncbi [Male genital tract infection: the point of view of the virologist]
    M Leruez-Ville
    Laboratoire de Virologie, université Paris Descartes EA MRT 3620, Faculté de Médecine AP HP, Hopital Necker Enfants Malades, 149, rue de Sevres, 75015 Paris, France
    Gynecol Obstet Fertil 33:684-90. 2005
    ..Recent advances in this field have allowed to offer Assisted reproductive techniques to couples with chronic viral infection, under strict and specific protocols. This paper presents an overview of these recent developments...
  48. ncbi Sexually transmitted hepatitis C virus superinfection in HIV/hepatitis C virus co-infected men who have sex with men
    Jade Ghosn
    AP HP, EA MRT 3620, Universite Paris Descartes, Department of Virology, Necker Hospital, Paris, France
    AIDS 22:658-61. 2008
    ..HCV serology and serum HCV RNA should be examined periodically in HIV-infected men who have sex with men engaging in high-risk sexual behaviours...
  49. ncbi Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare setting
    Juliette Pavie
    Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, Universite Paris Diderot, Paris, France
    PLoS ONE 5:e11581. 2010
    ..Several HIV rapid tests are now licensed in Europe but their sensitivity on total blood and/or oral fluid in routine healthcare settings is not known...
  50. ncbi Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)
    Christine Katlama
    Département des Maladies Infectieuses et Tropicales INSERM E 0214, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
    AIDS 18:217-26. 2004
    ..Both highly potent antiretroviral drug rescue therapy and treatment interruption have been suggested to be effective in patients with multiple treatment failure...
  51. ncbi Interleukin 2 treatment does not modify hepatitis B or C replication in human immunodeficiency virus-infected patients: results from a randomized control trial
    Vincent Thibault
    Hepatology 35:238-9. 2002
  52. ncbi [Is HIV more and more resistant?]
    Marie Laure Chaix
    Laboratoire de Virologie, Hopital Necker Enfants Malades, 75743 Paris 15
    Rev Prat 54:471-4. 2004